Datapoint: FDA Rejects Biocon’s NovoLog Biosimilar

The FDA recently rejected Biocon Biologics’ latest biosimilar insulin product, a copy of Novo Nordisk’s NovoLog, citing a need for additional data and pending improvements at the company’s manufacturing facilities. Biocon is the manufacturer of Semglee, a biosimilar for Sanofi’s insulin Lantus. As a short-acting mealtime insulin for the treatment of type 2 diabetes, NovoLog currently holds covered or better status for 74% of all insured lives. 52.5% of lives have preferred, unrestricted access to NovoLog.

SOURCE: MMIT Analytics, as of 1/18/23

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 30

Datapoint: BMS to Battle AstraZeneca in Court Over Yervoy-Imjudo Dispute

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 26

Datapoint: Elevance Health to Acquire BCBS Louisiana

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 25

Datapoint: Seagen Scores Colorectal Cancer Nod for Tukysa

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today